IDO1 and cancer: PD‐L1/2, TIGIT, and IDO1—all included within the 18‐gene TIS, which was developed as a pan‐cancer predictor of response to pembrolizumab [30]—were also found to independently predict improvement in DFS in the ddCTX arm of our analysis.